Skip to main content

Advertisement

ADVERTISEMENT

Y-90 Radioembolization Topic Center

Y-90 Radioembolization

Daniel B. Brown, MD, FSIR
Videos
04/12/2024

Featuring Daniel B. Brown, MD, FSIR

Featuring Daniel B. Brown, MD, FSIR ...
Daniel B. Brown, MD, FSIR, shares insights on an analysis of the RESiN study, evaluating the use of Y90 radioembolization for patients with hepatocellular carcinoma who had undergone previous resection.
Daniel B. Brown, MD, FSIR, shares insights on an analysis of the RESiN study, evaluating the use of Y90 radioembolization for patients with hepatocellular carcinoma who had undergone previous resection.
Daniel B. Brown, MD, FSIR,...
04/12/2024
IO Learning
Qian (Clark) Yu, MD, University of Chicago
Conference Coverage
04/12/2024

Featuring Qian (Clark) Yu, MD

Featuring Qian (Clark) Yu, MD
At the SIR 2024 Annual Meeting, Clark Yu, MD, shared data on the combination of transarterial radioembolization with systemic capecitabine for patients with unresectable cholangiocarcinoma.
At the SIR 2024 Annual Meeting, Clark Yu, MD, shared data on the combination of transarterial radioembolization with systemic capecitabine for patients with unresectable cholangiocarcinoma.
At the SIR 2024 Annual Meeting,...
04/12/2024
IO Learning
Andrew Kennedy, MD, Sarah Cannon Research Institute
Conference Coverage
04/03/2024

Featuring Andrew Kennedy, MD

Featuring Andrew Kennedy, MD
At the 2024 SIR Annual Meeting, Andrew Kennedy, MD, discusses the utilization of imageable glass Y90 microspheres in radioembolization for patients with hepatocellular carcinoma.
At the 2024 SIR Annual Meeting, Andrew Kennedy, MD, discusses the utilization of imageable glass Y90 microspheres in radioembolization for patients with hepatocellular carcinoma.
At the 2024 SIR Annual Meeting,...
04/03/2024
IO Learning
Ganguli CIO
Suvranu Ganguli, MD, FSIR presents notable 2022 studies on Y-90 for metastatic disease at the Symposium on Clinical Interventional Oncology.
01/06/2023
Tabori CIO
Nora Tabori, MD presents notable Y-90 studies at the Symposium on Clinical Interventional Oncology in 2022.
01/06/2023
Violari and Gandhi
Podcast
12/13/2022
In the latest offering from the SIO Corner, Dr Ripal Gandhi discusses his experiences building a successful Y-90 program along with recent advancements in Y-90 radioembolization.
In the latest offering from the SIO Corner, Dr Ripal Gandhi discusses his experiences building a successful Y-90 program along with recent advancements in Y-90 radioembolization.
In the latest offering from the...
12/13/2022
IO Learning
Purpose: The TheraSphere Global Dosimetry Steering Committee (DSC) reconvened to update the clinical and dosimetric recommendations for the treatment of unresectable hepatocellular carcin...
10/18/2022
Purpose: To evaluate the effectiveness, safety, and predictors of outcome of patients treated with yttrium-90 (90Y) radioembolization for hepatic involvement of metastatic melanoma. ...
10/18/2022
Late-breaking abstract / This study aims to evaluate the safety and efficacy of Yttrium-90 radioembolization of patients with liver-dominant metastatic melanoma.
10/17/2022
Video
10/12/2022
Dr Allison Aguado discusses current treatment options for pediatric primary hepatic malignancies, as well as her currently enrolling trial on clinical outcomes and quality of life after radioembolization in children with liver cancer.
Dr Allison Aguado discusses current treatment options for pediatric primary hepatic malignancies, as well as her currently enrolling trial on clinical outcomes and quality of life after radioembolization in children with liver cancer.
Dr Allison Aguado discusses...
10/12/2022
IO Learning
Dr Ripal Gandhi
SIR 2022
06/15/2022
"The difference between a patient with stable disease and a patient with a complete response really comes down to dosimetry." - Ripal Gandhi, MD, FSIR, FSVM, offers highlights from his Y-90 presentations at SIR 2022.
"The difference between a patient with stable disease and a patient with a complete response really comes down to dosimetry." - Ripal Gandhi, MD, FSIR, FSVM, offers highlights from his Y-90 presentations at SIR 2022.
"The difference between a...
06/15/2022
IO Learning

Video Presentations

Daniel B. Brown, MD, FSIR
Videos
04/12/2024

Featuring Daniel B. Brown, MD, FSIR

Featuring Daniel B. Brown, MD, FSIR ...
Daniel B. Brown, MD, FSIR, shares insights on an analysis of the RESiN study, evaluating the use of Y90 radioembolization for patients with hepatocellular carcinoma who had undergone previous resection.
Daniel B. Brown, MD, FSIR, shares insights on an analysis of the RESiN study, evaluating the use of Y90 radioembolization for patients with hepatocellular carcinoma who had undergone previous resection.
Daniel B. Brown, MD, FSIR,...
04/12/2024
IO Learning
Ganguli CIO
Suvranu Ganguli, MD, FSIR presents notable 2022 studies on Y-90 for metastatic disease at the Symposium on Clinical Interventional Oncology.
01/06/2023
Tabori CIO
Nora Tabori, MD presents notable Y-90 studies at the Symposium on Clinical Interventional Oncology in 2022.
01/06/2023
Video
10/12/2022
Dr Allison Aguado discusses current treatment options for pediatric primary hepatic malignancies, as well as her currently enrolling trial on clinical outcomes and quality of life after radioembolization in children with liver cancer.
Dr Allison Aguado discusses current treatment options for pediatric primary hepatic malignancies, as well as her currently enrolling trial on clinical outcomes and quality of life after radioembolization in children with liver cancer.
Dr Allison Aguado discusses...
10/12/2022
IO Learning
Dr Ripal Gandhi
SIR 2022
06/15/2022
"The difference between a patient with stable disease and a patient with a complete response really comes down to dosimetry." - Ripal Gandhi, MD, FSIR, FSVM, offers highlights from his Y-90 presentations at SIR 2022.
"The difference between a patient with stable disease and a patient with a complete response really comes down to dosimetry." - Ripal Gandhi, MD, FSIR, FSVM, offers highlights from his Y-90 presentations at SIR 2022.
"The difference between a...
06/15/2022
IO Learning
Sabina Amin, MD discusses the current research findings on SIR-Spheres microspheres.
02/17/2022
Nora Tabori, MD, Edward Kim, MD, and Riad Salem, MD present current thoughts on Y-90 dosimetry based on the EPOCH trial.
02/16/2022
Osman Ahmed, MD, University of Chicago Medicine
Videos
05/09/2024

Featuring Osman Ahmed, MD

Featuring Osman Ahmed, MD
Osman Ahmed, MD, gives an overview of histotripsy and explains the recent #HOPE4LIVER trial, looking the safety and efficacy of this technique for liver tumors.
Osman Ahmed, MD, gives an overview of histotripsy and explains the recent #HOPE4LIVER trial, looking the safety and efficacy of this technique for liver tumors.
Osman Ahmed, MD, gives an...
05/09/2024
IO Learning
Christos Georgiades, MD, PhD, Johns Hopkins Hospital
Videos
05/09/2024

Featuring Christos Georgiades, MD, PhD

Featuring Christos Georgiades, MD, Ph...
Christos Georgiades, MD, PhD, explains the physics of histotripsy and how this technique differs from existing interventional oncology treatments.
Christos Georgiades, MD, PhD, explains the physics of histotripsy and how this technique differs from existing interventional oncology treatments.
Christos Georgiades, MD, PhD,...
05/09/2024
IO Learning
Daniel B. Brown, MD, FSIR
Videos
04/12/2024

Featuring Daniel B. Brown, MD, FSIR

Featuring Daniel B. Brown, MD, FSIR ...
Daniel B. Brown, MD, FSIR, shares insights on an analysis of the RESiN study, evaluating the use of Y90 radioembolization for patients with hepatocellular carcinoma who had undergone previous resection.
Daniel B. Brown, MD, FSIR, shares insights on an analysis of the RESiN study, evaluating the use of Y90 radioembolization for patients with hepatocellular carcinoma who had undergone previous resection.
Daniel B. Brown, MD, FSIR,...
04/12/2024
IO Learning
AJ Gunn, MD, University of Alabama at Birmingham
Videos
04/11/2024

Featuring AJ Gunn, MD

Featuring AJ Gunn, MD
At the 2024 SIR Annual Meeting, AJ Gunn, MD, University of Alabama at Birmingham, discussed treatment for patients with central renal tumors.
At the 2024 SIR Annual Meeting, AJ Gunn, MD, University of Alabama at Birmingham, discussed treatment for patients with central renal tumors.
At the 2024 SIR Annual Meeting,...
04/11/2024
IO Learning
Constantino Peña, MD, Miami Cancer Institute
Videos
03/21/2024

Featuring Constantino Peña, MD

Featuring Constantino Peña, MD ...
Constantino Peña, MD, discusses the importance of a multidisciplinary approach within the field of interventional oncology.
Constantino Peña, MD, discusses the importance of a multidisciplinary approach within the field of interventional oncology.
Constantino Peña, MD, discusses...
03/21/2024
IO Learning
Nadine Abi-Jaoudeh, MD, University of California, Irvine
Videos
03/13/2024

Featuring Nadine Abi-Jaoudeh, MD

Featuring Nadine Abi-Jaoudeh, MD ...
Nadine Abi-Jaoudeh, MD, shares her top clinical pearls for drug-eluting bead transarterial chemoembolization.
Nadine Abi-Jaoudeh, MD, shares her top clinical pearls for drug-eluting bead transarterial chemoembolization.
Nadine Abi-Jaoudeh, MD, shares...
03/13/2024
IO Learning
Rahul Sheth, MD, MD Anderson Cancer Center
Videos
03/06/2024

Featuring Rahul Sheth, MD

Featuring Rahul Sheth, MD
Rahul Sheth, MD, explains the uses and limitations to immunotherapy within oncology and how intratumoral delivery of these agents may change the field of interventional oncology.
Rahul Sheth, MD, explains the uses and limitations to immunotherapy within oncology and how intratumoral delivery of these agents may change the field of interventional oncology.
Rahul Sheth, MD, explains the...
03/06/2024
IO Learning
Jashodeep Datta, MD, Sylvester Comprehensive Cancer Center
Videos
02/27/2024

Featuring Jashodeep Datta, MD

Featuring Jashodeep Datta, MD
Jashodeep Datta, MD, shares insights on the use of hepatic artery infusion for colorectal cancer that has metastasized to the liver, and how it compares to transarterial radioembolization with Y90.
Jashodeep Datta, MD, shares insights on the use of hepatic artery infusion for colorectal cancer that has metastasized to the liver, and how it compares to transarterial radioembolization with Y90.
Jashodeep Datta, MD, shares...
02/27/2024
IO Learning
Thierry de Baère, MD, Gustave Roussy
Videos
02/22/2024

Featuring Thierry de Baère, MD

Featuring Thierry de Baère, MD ...
Thierry de Baère, MD, shares his top 5 tips to keep in mind when administering transarterial chemoembolization.
Thierry de Baère, MD, shares his top 5 tips to keep in mind when administering transarterial chemoembolization.
Thierry de Baère, MD, shares his...
02/22/2024
IO Learning
Christos Georgiades, MD, PhD, Johns Hopkins University
Videos
02/07/2024

Featuring Christos Georgiades, MD, PhD

Featuring Christos Georgiades, MD, Ph...
Christos Georgiades, MD, PhD, shares why it is important for interventional oncologists to understand the physics of different ablation modalities.
Christos Georgiades, MD, PhD, shares why it is important for interventional oncologists to understand the physics of different ablation modalities.
Christos Georgiades, MD, PhD,...
02/07/2024
IO Learning

CIO Abstracts

Purpose: The TheraSphere Global Dosimetry Steering Committee (DSC) reconvened to update the clinical and dosimetric recommendations for the treatment of unresectable hepatocellular carcin...
10/18/2022
Purpose: To evaluate the effectiveness, safety, and predictors of outcome of patients treated with yttrium-90 (90Y) radioembolization for hepatic involvement of metastatic melanoma. ...
10/18/2022
Late-breaking abstract / This study aims to evaluate the safety and efficacy of Yttrium-90 radioembolization of patients with liver-dominant metastatic melanoma.
10/17/2022
Purpose: Transarterial radioembolization (TARE) is commonly used for treatment of neuroendocrine tumor liver metastases (NETLMs). Hormonal release causing hemodynamic instability and carc...
11/15/2021
Purpose: To evaluate patient safety and treatment outcomes of radiation segmentectomy for metastatic disease to the liver.
11/15/2021
Purpose: The aim of this study is to examine the clinical outcomes of yttrium-90 (Y90) transarterial radioembolization (TARE) of primary hepatocellular carcinoma (HCC) through evaluation ...
11/15/2021
Purpose: 90Y radioembolization has been studied as an effective therapy for neuroendocrine liver metastases (NELM). We aim to further characterize treatment outcomes as it relates to the ...
11/15/2021
Purpose: Delineation of liver, hepatic lobes, and gross tumor volumes (GTV) is necessary for activity calculation of resin Y-90 microsphere radioembolization. Hepatic lobe delineation can...
11/15/2021
Purpose: The purpose of this study was to investigate the impact of vascularity on radioembolic performance in a simulated liver tumor using 20-30μm diameter glass Y-89 microspheres (MS)....
11/15/2021
Purpose: To describe the use of Y-90 radioembolization (Y-90 RE) for unresectable high risk hepatic adenoma in a patient with chronic liver disease.
11/15/2021
Ebstesam Nafie
CIO2023 Highlights
12/14/2023
Ebstesam Nafie discusses her CIO2023 abstract, "CIO 2023-24 A Case Report of Successful Treatment of Metastatic Liposarcoma with Pulsed Electric Fields."
Ebstesam Nafie discusses her CIO2023 abstract, "CIO 2023-24 A Case Report of Successful Treatment of Metastatic Liposarcoma with Pulsed Electric Fields."
Ebstesam Nafie discusses her...
12/14/2023
IO Learning
Palliative Ablation and Kyphoplasty for a Suspected Metastatic Fracture
CIO2023 Highlights
11/30/2023
Hanna Thompson discusses her CIO2023 abstract, "CIO 2023-30 Palliative Ablation and Kyphoplasty for a Suspected Metastatic Fracture."
Hanna Thompson discusses her CIO2023 abstract, "CIO 2023-30 Palliative Ablation and Kyphoplasty for a Suspected Metastatic Fracture."
Hanna Thompson discusses her...
11/30/2023
IO Learning
Thyroid Ablation after Thyroid Cancer Recurrence in a Hostile Neck
CIO2023 Highlights
11/30/2023
Hanna Thompson discusses her CIO2023 abstract, "CIO 2023-31 Thyroid Ablation after Thyroid Cancer Recurrence in a Hostile Neck ."
Hanna Thompson discusses her CIO2023 abstract, "CIO 2023-31 Thyroid Ablation after Thyroid Cancer Recurrence in a Hostile Neck ."
Hanna Thompson discusses her...
11/30/2023
IO Learning
Concurrent Liver Ablation and Paracentesis in Patients with Preexisting Ascites
CIO2023 Highlights
11/30/2023
Hanna Thompson discusses her CIO2023 abstract, "Concurrent Liver Ablation and Paracentesis in Patients with Preexisting Ascites."
Hanna Thompson discusses her CIO2023 abstract, "Concurrent Liver Ablation and Paracentesis in Patients with Preexisting Ascites."
Hanna Thompson discusses her...
11/30/2023
IO Learning
Brendan Ryu
CIO2023 Highlights
11/14/2023
Brendan Ryu discusses his CIO2023 abstract, "CIO 2023-23 Efficacy and Safety of Intraarterial Chemotherapy in Locally Aggressive Breast Cancers: A 10-Year Literature Review ."
Brendan Ryu discusses his CIO2023 abstract, "CIO 2023-23 Efficacy and Safety of Intraarterial Chemotherapy in Locally Aggressive Breast Cancers: A 10-Year Literature Review ."
Brendan Ryu discusses his...
11/14/2023
IO Learning
Ashwin Mahendra
CIO2023 Highlights
11/13/2023
Ashwin Mahendra discusses his CIO2023 abstract, "CIO 2023-35 Percutaneous Ablation of Colorectal Liver Metastasis in a Patient With Hereditary Hemorrhagic Telangiectasia."
Ashwin Mahendra discusses his CIO2023 abstract, "CIO 2023-35 Percutaneous Ablation of Colorectal Liver Metastasis in a Patient With Hereditary Hemorrhagic Telangiectasia."
Ashwin Mahendra discusses his...
11/13/2023
IO Learning
Purpose: To report outcomes of an institutional downstaging protocol for intrahepatic cholangiocarcinoma (iCCA) using radioembolization (TARE), gemcitabine, cisplatin, and capecitabine co...
11/02/2023
Purpose: To identify factors of incomplete treatment after segmental transarterial radioembolization (TARE) for treatment-naïve and solitary hepatocellular carcinoma (HCC)
11/02/2023
Purpose: The procedural and clinical outcomes of a transradial approach (TRA) versus a transfemoral approach (TFA) for interventional oncology (IO) procedures remain unclear.
11/02/2023
Purpose: Long term care of patient's with complicated disease processes often incurs significant financial burden. This burden if often complicated with misuse or failure of medical devic...
11/02/2023

Podcasts and Interviews

Violari and Gandhi
Podcast
12/13/2022
In the latest offering from the SIO Corner, Dr Ripal Gandhi discusses his experiences building a successful Y-90 program along with recent advancements in Y-90 radioembolization.
In the latest offering from the SIO Corner, Dr Ripal Gandhi discusses his experiences building a successful Y-90 program along with recent advancements in Y-90 radioembolization.
In the latest offering from the...
12/13/2022
IO Learning
TARGET
Podcast and Video
06/05/2021
TARGET is a global real-world study set across eight countries that confirms TheraSphere as safe and effective treatment for HCC, demonstrating reproducible clinical outcomes across a broad patient population. Professor Marnix Lam and Dr....
TARGET is a global real-world study set across eight countries that confirms TheraSphere as safe and effective treatment for HCC, demonstrating reproducible clinical outcomes across a broad patient population. Professor Marnix Lam and Dr....
TARGET is a global real-world...
06/05/2021
IO Learning
LEGACY
Podcasts
12/10/2020
In this episode of IOL Radio, we discuss the results of the LEGACY Study, a robust multicenter study confirming Boston Scientific’s TheraSphere™ as a neoadjuvant or standalone therapy in treating hepatocellular carcinoma.
In this episode of IOL Radio, we discuss the results of the LEGACY Study, a robust multicenter study confirming Boston Scientific’s TheraSphere™ as a neoadjuvant or standalone therapy in treating hepatocellular carcinoma.
In this episode of IOL Radio, we...
12/10/2020
IO Learning
Interview
07/15/2019
Peptide receptor radionuclide therapy (PRRT) is a potential therapy option for patients with metastatic neuroendocrine tumor, but questions remain about patient selection and treatment decisions in conjunction with arterial therapy,...
Peptide receptor radionuclide therapy (PRRT) is a potential therapy option for patients with metastatic neuroendocrine tumor, but questions remain about patient selection and treatment decisions in conjunction with arterial therapy,...
Peptide receptor radionuclide...
07/15/2019
IO Learning
Katerina Lee, MD
Podcasts
06/20/2024
Katerina Lee, MD
Andrew Kolarich, MD
In this episode of the SIO Corner podcast, Katerina Lee, MD, discusses her study regarding the use of a smartphone augmented reality guidance system for composite ablation margins in phantom models.
In this episode of the SIO Corner podcast, Katerina Lee, MD, discusses her study regarding the use of a smartphone augmented reality guidance system for composite ablation margins in phantom models.
In this episode of the SIO...
06/20/2024
IO Learning
Dania Daye, MD, PhD, Massachusetts General Hospital
Podcasts
04/23/2024

Featuring Dania Daye, MD, PhD

Featuring Dania Daye, MD, PhD
Dania Daye, MD, PhD, joins this episode of the SIO Corner podcast to share insights on how AI can be used to improve clinical practice in interventional oncology and other medical fields.
Dania Daye, MD, PhD, joins this episode of the SIO Corner podcast to share insights on how AI can be used to improve clinical practice in interventional oncology and other medical fields.
Dania Daye, MD, PhD, joins this...
04/23/2024
IO Learning
Q&As
03/25/2024

Featuring Murat Dökdök, MD

Featuring Murat Dökdök, MD
Dr Murat Dökdök discusses the importance of compliance with interventional oncology accreditation standards among interventional radiologists.
Dr Murat Dökdök discusses the importance of compliance with interventional oncology accreditation standards among interventional radiologists.
Dr Murat Dökdök discusses the...
03/25/2024
IO Learning
Constantino Peña, MD, Miami Cancer Institute
Videos
03/21/2024

Featuring Constantino Peña, MD

Featuring Constantino Peña, MD ...
Constantino Peña, MD, discusses the importance of a multidisciplinary approach within the field of interventional oncology.
Constantino Peña, MD, discusses the importance of a multidisciplinary approach within the field of interventional oncology.
Constantino Peña, MD, discusses...
03/21/2024
IO Learning
Jack Jennings, MD, PhD, Washington University in St Louis
Videos
02/06/2024

Featuring Jack Jennings, MD, PhD

Featuring Jack Jennings, MD, PhD ...
At the 2024 SIO Annual Meeting, Jack Jennings, MD, PhD, discussed the role of the interventional oncologist when treating primary or metastatic sarcomas of the bone or soft tissue.
At the 2024 SIO Annual Meeting, Jack Jennings, MD, PhD, discussed the role of the interventional oncologist when treating primary or metastatic sarcomas of the bone or soft tissue.
At the 2024 SIO Annual Meeting,...
02/06/2024
IO Learning
Riccardo Lencioni, MD, University of Pisa School of Medicine
Videos
01/23/2024

Featuring Riccardo Lencioni, MD

Featuring Riccardo Lencioni, MD ...
Ricardo Lencioni, MD, shares results from the phase 3 EMERALD-1 study which found the addition of durvalumab and bevacizumab to TACE improved progression-free survival among patients with hepatocellular carcinoma, compared with TACE alone.
Ricardo Lencioni, MD, shares results from the phase 3 EMERALD-1 study which found the addition of durvalumab and bevacizumab to TACE improved progression-free survival among patients with hepatocellular carcinoma, compared with TACE alone.
Ricardo Lencioni, MD, shares...
01/23/2024
Oncology
Dr. Kavi Krishnasamy and Dr. Vijay Ramalingam
Podcast
01/03/2024
In this episode of the IOL Radio Podcast, Kavi Krishnasamy, MD, interventional radiologist at Columbia University Irving Medical Center, and his guest Vijay Ramalingam, MD, IR professional at Beth Israel Deaconess Medical Center, discuss the...
In this episode of the IOL Radio Podcast, Kavi Krishnasamy, MD, interventional radiologist at Columbia University Irving Medical Center, and his guest Vijay Ramalingam, MD, IR professional at Beth Israel Deaconess Medical Center, discuss the...
In this episode of the IOL Radio...
01/03/2024
IO Learning
Managing Y90 to the GI Tract with Dr. Oleksandra Kutsenko
Interview
12/08/2023
In this brief interview, Oleksandra Kutsenko, MD at Red Rock Radiology Associates, shares how she successfully manages Y90 to the GI tract.
In this brief interview, Oleksandra Kutsenko, MD at Red Rock Radiology Associates, shares how she successfully manages Y90 to the GI tract.
In this brief interview,...
12/08/2023
IO Learning
Dr. Riad Salem
Interview
12/07/2023
In this interview with Riad Salem, MD, Chief of Vascular and Interventional Radiology in the Department of Radiology at Northwestern Medicine, we discuss the future of IO, unique approaches to Y-90, and what's next for the interventional...
In this interview with Riad Salem, MD, Chief of Vascular and Interventional Radiology in the Department of Radiology at Northwestern Medicine, we discuss the future of IO, unique approaches to Y-90, and what's next for the interventional...
In this interview with Riad...
12/07/2023
IO Learning
Dr. Edward Kim
CIO2023 Highlights
12/06/2023
In this interview feature, Dr. Edward Kim discusses HCC highlights, flow-diversion techniques, and running an outpatient IO lab.
In this interview feature, Dr. Edward Kim discusses HCC highlights, flow-diversion techniques, and running an outpatient IO lab.
In this interview feature, Dr....
12/06/2023
IO Learning

Advertisement

Advertisement

Advertisement